Maxim Group Reiterates Buy Rating on Zevra Therapeutics
Maxim Group maintains its buy rating on Zevra Therapeutics with a $35 price target, a 178.88% upside from the current price.
Key Points
- Maxim Group reiterated its buy rating on Zevra Therapeutics with a $35 price target on June 10, 2026.
- Maxim Group's $35 price target implies 178.88% upside from Zevra Therapeutics, Inc.'s ($ZVRA) current $12.55 share price.
- Zevra Therapeutics, trading at $12.96, has a market cap of $747.8 million and a P/E ratio of 6.29.
- Insider transactions included Timothy Sangiovanni buying 60,000 shares on May 28, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Maxim Group has reiterated its buy rating for Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), maintaining a price target of $35. This update from analyst Jason McCarthy was announced on June 10, 2026, as the stock traded at $12.96.
Zevra Therapeutics, Inc. Stock Up 8.5%
Shares of Zevra Therapeutics are trading around $12.96, with a market capitalization of approximately $747.8 million. The company's P/E ratio is 6.29, while the forward P/E is 10.59. The stock's beta is 0.894, indicating it is less volatile than the market. Over the past 52 weeks, the stock has ranged from a low of $7.16 to a high of $14.27. Zevra's 50-day moving average is $10.71, and its 200-day moving average stands at $9.52.
$ZVRA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Zevra reported revenue of $122.3 million, reflecting a growth rate of 77.5%. The company's earnings per share (EPS) is $2.01, with a net margin of 101.6% and return on equity (ROE) of 100.7%. Investors are looking forward to the next earnings announcement scheduled for May 6, 2026.
Insider Buying and Selling at Zevra Therapeutics, Inc.
Insider activity at Zevra includes Timothy Sangiovanni, SVP of Finance & Corp Controller, purchasing a total of 60,000 shares on May 28, 2026. Additionally, Rahsaan Thompson, Chief Legal & Compliance, sold 1,794 shares at $11.30 on May 11, 2026, under a planned transaction.
Analysts Set New Price Targets
On June 10, 2026, Maxim Group maintained its buy rating for Zevra Therapeutics with a $35 price target. On the same day, Guggenheim also maintained a buy rating with a $29 target. Canaccord Genuity reiterated their buy rating with a $29 target on June 11, 2026. The consensus among analysts is a strong buy, with an average target price of $27.89 from nine analysts.
About Zevra Therapeutics
Zevra Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing treatments for rare diseases using its Ligand Activated Technology platform. The company's lead products include KP1077 for idiopathic hypersomnia and narcolepsy, Celiprolol for vascular Ehlers Danlos syndrome, and AZSTARYS for ADHD. Zevra also develops OLPRUVA for urea cycle disorders and MIPLYFFA for Niemann-Pick disease type C. Led by CEO Neil F. McFarlane, Zevra employs 61 individuals.
Bottom Line
Maxim Group's reiteration of a buy rating with a $35 target reflects continued confidence in Zevra Therapeutics' potential. Investors monitor these updates for insights into the company's valuation and market perception. However, it's important to remember that analyst ratings are based on past performance and projections, which may not reflect current conditions.
Get Zevra Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ZVRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.